UK’s first commercial synthetic biology foundry begins production

pharmafile | April 7, 2016 | News story | Manufacturing and Production, Research and Development Biological, biologics, foundry, synbicite 

SynbiCITE’s has begun production at the UK’s first commercial synthetic biology foundry.

The site provides automated end-to-end design, construction and validation of synthetic biologic components combined with a unique open access and sharing software which allows researchers to speed-up innovation by sharing their biodesign protocols with different labs around the world.

Dr Stephen Chambers, CEO, describes the aims of the SynbiCITE Foundry: “To accelerate the translation of synthetic biology R&D into the marketplace. The Foundry has been created and built to operate as a ‘cloud lab’ to support synthetic biologists across the UK and is for everyone in the business of synthetic biology and who can use synthetic biology in their business.

“These remote users send their biodesigns to the Foundry, which executes the work and delivers the data or prototype to the biodesigner once the work is complete. The Foundry provides a ‘maker space’ for entrepreneurial scientists looking to commercialise their research, ready access to state-of-the-art automation for SMEs, and is a facility for large and small companies to explore the enormous potential of synthetic biology.”

Sean Murray

Related Content

AstraZeneca to retire MedImmune brand amid restructuring

AstraZeneca is retiring the MedImmune brand as part of a restructuring that will see biologics …


Boehringer injects €230 million in new Biologicals Development Center

Prominent industry player Boehringer Ingelheim has unveiled plans to invest €230 million into the construction …


AbbVie adds biologic production capability to Singapore facility

AbbVie has expanded the operational capability of its facility located at the Tuas Biomedical Park …

Latest content